What is Pacific Edge?
Pacific Edge stands as a unique entity in the global molecular diagnostics landscape, specializing in a comprehensive suite of tests for bladder cancer. Its proprietary Cxbladder technology offers highly accurate, non-invasive, and cost-effective diagnostic tools that address various needs across the patient pathway, from initial investigation of hematuria to monitoring disease recurrence. The company is actively positioning Cxbladder as the preferred diagnostic standard for clinicians and urologists, observing escalating demand from both private and public healthcare systems.
How much funding has Pacific Edge raised?
Pacific Edge has raised a total of $36.7M across 2 funding rounds:
Stock/Share Issuance
$16M
Other Financing Round
$20.7M
Stock/Share Issuance (2025): $16M, investors not publicly disclosed
Other Financing Round (2025): $20.7M, investors not publicly disclosed
What's next for Pacific Edge?
The substantial enterprise-level funding and recent strategic investment signal a strong vote of confidence in Pacific Edge's technology and market strategy. This capital infusion is expected to accelerate the company's growth, potentially enabling broader market penetration, further research and development into its diagnostic platforms, and expansion of its commercial operations. The focus will likely remain on solidifying Cxbladder's position as a leading diagnostic tool in bladder cancer management, driving adoption and improving patient outcomes through advanced molecular insights.
See full Pacific Edge company page
